Loading clinical trials...
Loading clinical trials...
A 2-Part, Randomized, Phase I Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects
Conditions
Interventions
Y-2 Sublingual Tablet
Y-2 Sublingual Tablet
+4 more
Locations
1
United States
Parexel International Los Angeles Early Phase Clinical Unit
Glendale, California, United States
Start Date
September 6, 2023
Primary Completion Date
November 21, 2023
Completion Date
December 5, 2023
Last Updated
December 12, 2023
NCT07310264
NCT06716502
NCT06290258
NCT00090662
NCT07483606
NCT06342713
Lead Sponsor
Simcere Pharmaceutical Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions